Denali Therapeutics Inc. Common Stock (DNLI) Stock Price, Quote & AI Analysis
Live DNLI stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Denali Therapeutics Inc. Common Stock.
TradeVae provides AI-driven analysis and real-time market intelligence for Denali Therapeutics Inc. Common Stock (DNLI), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
Denali Therapeutics Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
Denali Therapeutics Inc. Common Stock Overview
Company information
Company Overview
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Company Details
Technical Indicators
Key technical analysis metrics and signals
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
Denali Therapeutics Inc. Common Stock Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...